Description

Tamsulosin HCI 

Drug class: Alpha blockers

• Tamsulosin with a low propensity for side effects, is relatively selective for α_{1A and D}-adrenoceptors over α_1B-adrenoceptors.

• The long-term efficacy and safety of tamsulosin in BPH (benign prostatic hyperplasia), evident from previous shorter-term and 4-year long-term clinical trials are proven.

• This α_1A subtype selective adrenergic receptor blocker is a viable long-term alternative to surgery.

Dutasteride 

Drug class: 5-alpha reductase inhibitors

• Dutasteride is the first dual inhibitor of both 5α reductase isoenzymes.

• Improves urinary symptoms and flow rate.

• Also associated with significant improvements in BPH Impact Index (BII) score, reflecting improvements in quality of life for men with BPH.

• Advantageous in the chemoprevention of prostate cancer

COMBINATION:

• Combination therapy with dutasteride and tamsulosin was significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression.
• Combination therapy was significantly superior to tamsulosin monotherapy (but not dutasteride monotherapy) at reducing the relative risk of AUR (acute urinary retention) or BPH-related surgery.

• Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies. 

• Combined therapy with dutasteride plus tamsulosin provided better long-term (up to 4years) control of both storage and voiding LUTS compared with tamsulosin monotherapy.